CJC-1295 (No DAC) / Ipamorelin 5mg / 5mg
Dual peptide research blend studied for coordinated growth hormone–releasing and ghrelin receptor signaling pathways.
Compound Overview
This research formulation combines CJC-1295 (No DAC), a synthetic growth hormone–releasing hormone (GHRH) analogue, with Ipamorelin, a selective growth hormone secretagogue and ghrelin receptor agonist. Together, these peptides are studied for their interaction within endogenous growth hormone regulatory systems.
CJC-1295 (No DAC) targets GHRH receptors in the anterior pituitary to support pulsatile growth hormone signaling models. Ipamorelin acts on the GHS-R1a receptor, evaluated for selective stimulation of growth hormone release in experimental endocrine research. Combined studies often examine multi-receptor pathway activation and coordinated hormone signaling dynamics.
CJC-1295 Research Focus
Studied for GHRH receptor activation, pulsatile GH secretion models, and pituitary-endocrine pathway research.
Ipamorelin Research Focus
Evaluated as a ghrelin receptor agonist for selective growth hormone pathway stimulation in controlled laboratory studies.
Combination Research Applications
Included in experimental protocols examining dual-pathway GH regulation and endocrine signaling interactions.
Product Specifications
- Product Name: CJC-1295 (No DAC) / Ipamorelin Blend
- CJC-1295 Content: 5mg
- Ipamorelin Content: 5mg
- Total Peptide Content: 10mg per vial
- Form: Lyophilized peptide powder blend
- Intended Use: Research use only
Be the first to review “CJC/IPA 5MG/5MG”
Related products
Reviews
There are no reviews yet.